Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Transmission and prevention news

Show

From To
As EU Approval Moves Closer Are Governments Prepared For PrEP?

On Friday the EU's Committee for Medicinal Products for Human Use (CHMP) announced its positive opinion on Gilead’s HIV pre-exposure prophylaxis product Truvada PrEP. But with many European governments trying to control healthcare costs, the biggest issue facing Truvada PrEP might not be approval but rather reimbursement.

Published
7 hours ago
From
Seeking Alpha
Mapping local HIV epidemics can help target resources to areas with the greatest need

Global health agencies have recently put a new emphasis on geography. UNAIDS have called for programmes to focus on “location and population”. PEPFAR (The US President's Emergency

Published
26 July 2016
By
Roger Pebody
Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most

Young adults taking Truvada for pre-exposure prophylaxis (PrEP) experienced a modest decrease in bone mineral density early on, but this stabilised after a year and those who stopped

Published
26 July 2016
By
Liz Highleyman
'Test and treat': large study fails to show an impact on new HIV infections

The first major research study of ‘test and treat’ as a public health intervention to report its final results has found that the strategy failed to reduce

Published
23 July 2016
By
Roger Pebody
European CHMP Adopts Positive Opinion on Truvada® for Pre-Exposure Prophylaxis

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Type II variation application for once-daily Truvada® (emtricitabine 200 mg/tenofovir disoproxil 245 mg) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis, or PrEP.

Published
22 July 2016
From
Gilead press release
Australia adopts ambitious plan to use PrEP to ‘virtually eliminate’ HIV by 2020

Australia plans an ambitious programme of pre-exposure prophylaxis (PrEP) provision for gay men at high risk of HIV, with the aim of ‘virtually eliminating’ HIV in the

Published
21 July 2016
By
Gus Cairns
HIV Drug Pricing Protest Interrupts PrEP Session at AIDS 2016

Protesters against the high cost of antiretroviral drugs joined forces and marched together today, interrupting a research presentation today at the 21st International AIDS Conference (AIDS 2016).

Published
21 July 2016
From
BETA blog
South Africa launches SheConquers prevention campaign for increased focus on young women and adolescent girls

Responding to the heightened vulnerability of young women and adolescent girls to HIV, the Government of South Africa has launched a nationwide HIV prevention campaign. Entitled SheConquers, the three-year, multimillion rand campaign was launched at a session hosted by the South African Ministry of Health during the 21st International AIDS Conference, taking place in Durban, South Africa.

Published
21 July 2016
From
UNAIDS
PrEP can further reduce the risk of HIV infection after a partner starts treatment

Offering Truvada pre-exposure prophylaxis (PrEP) to the HIV-negative partner in a serodiscordant couple during the first six months after the HIV-positive partner starts antiretroviral therapy (ART) can

Published
21 July 2016
By
Liz Highleyman
Young gay men can do well on PrEP, but may need more support

Young gay and bisexual men had good adherence to Truvada for pre-exposure prophylaxis (PrEP) during the first few months of a demonstration project with close monitoring, but adherence

Published
21 July 2016
By
Liz Highleyman
← First12345...487Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close